Pluri, Inc.

Is Pluri, Inc. overvalued or undervalued?

As of May 13, 2025, Pluri, Inc. is considered a risky investment due to its negative financial metrics, including a Price to Book Value of -8.32 and an EV to EBITDA ratio of -1.69, alongside poor stock performance with a 1-year return of -13.35% compared to the S&P 500's 17.14%.

As of 13 May 2025, the valuation grade for Pluri, Inc. has moved from does not qualify to risky, indicating a deteriorating outlook. The company is overvalued, as reflected by its negative Price to Book Value of -8.32 and an EV to EBITDA ratio of -1.69, both of which suggest significant financial distress. Additionally, the EV to Sales ratio stands at 34.89, indicating that the market is pricing the company at an extremely high multiple relative to its sales.<BR><BR>In comparison to its peers, Pluri, Inc. has a less favorable EV to EBITDA ratio than Equillium, Inc. at -4.9420 and OncoCyte Corp. at -2.1276, highlighting its relative weakness within the industry. Furthermore, the company's recent stock performance has been poor, with a 1-year return of -13.35% compared to the S&P 500's 17.14%, reinforcing the notion that Pluri, Inc. is struggling significantly in the market.

Is Pluri, Inc. technically bullish or bearish?

As of September 12, 2025, Pluri, Inc. has shifted to a neutral trend with mixed signals, showing mild bearishness in weekly MACD and RSI, while underperforming the S&P 500 with a 1-week return of -12.41% compared to 1.05%.

As of 12 September 2025, the technical trend for Pluri, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across different indicators. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish. The weekly RSI is bearish, and both the weekly and monthly Bollinger Bands indicate bearish conditions. Daily moving averages show a mildly bullish trend. The KST is mildly bearish on a weekly basis and bearish monthly, while the Dow Theory shows no trend weekly and mildly bearish monthly. <BR><BR>In terms of performance, Pluri, Inc. has underperformed compared to the S&P 500 across multiple periods, with a 1-week return of -12.41% versus the S&P 500's 1.05%, and a 1-year return of -13.35% compared to 17.14% for the index.

How big is Pluri, Inc.?

As of Jun 18, Pluri, Inc. has a market capitalization of 33.21 million, with net sales of 1.04 million and a net profit of -21.34 million over the last four quarters. As of Jun 24, the company reported shareholder's funds of 0.10 million and total assets of 39.53 million.

Market Cap: As of Jun 18, Pluri, Inc. has a market capitalization of 33.21 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Pluri, Inc. reported net sales of 1.04 million and a net profit of -21.34 million.<BR><BR>Balance Sheet Snapshot: As of Jun 24, the company reported shareholder's funds of 0.10 million and total assets of 39.53 million.

What does Pluri, Inc. do?

Pluri, Inc. develops placenta-based cell therapy products for ischemic, inflammatory, and hematologic conditions, operating as a micro-cap company with a market cap of $33.21 million. As of March 2025, it reported net sales of $0 million and a net loss of $6 million.

Overview: <BR>Pluri, Inc. is a developer of placenta-based cell therapy product candidates for the treatment of various ischemic, inflammatory, and hematologic conditions, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 33.21 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.25 <BR>Return on Equity: 480.69% <BR>Price to Book: -7.42<BR><BR>Contact Details: <BR>Address: Matam Advanced Technology Park, Building No. 5 HAIFA None : 3508409 <BR>Tel: ['972 74 7108600', '1 972 7107194'] <BR>Fax: 972 74 7108765 <BR>Website: http://www.pluristem.com/

Should I buy, sell or hold Pluri, Inc.?

Who are in the management team of Pluri, Inc.?

As of March 2022, the management team of Pluri, Inc. includes Zalman Aberman (Executive Chairman), Yaky Yanay (CEO), Doron Shorrer (Lead Independent Director), Rami Levy, Maital Shemesh-Rasmussen, Isaac Braun, and Mark Germain (Independent Directors). They oversee the company's strategic direction and governance.

As of March 2022, the management team of Pluri, Inc. includes the following individuals:<BR><BR>- Mr. Zalman Aberman, Executive Chairman of the Board<BR>- Mr. Yaky Yanay, President, Chief Executive Officer, and Director<BR>- Mr. Doron Shorrer, Lead Independent Director<BR>- Mr. Rami Levy, Director<BR>- Ms. Maital Shemesh-Rasmussen, Director<BR>- Mr. Isaac Braun, Independent Director<BR>- Mr. Mark Germain, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and governance.